Co-D Therapeutics, Inc. ("Co-D") was incorporated in response to the unmet medical need in current cancer therapy and the need to improve patients' lives. Co-D is an innovative drug development company dedicated to bringing to market first-in-class, combination nanomedicines with high safety profiles to treat cancer.Learn More
We anticipate that Co-D’s platform technology will generate multiple products in the future. Co-D is seeking to establish strategic partnerships that are aligned with our business strategy to develop the company’s nano-medicine programs.
Co-D Therapeutics’ core polymeric micelle technology offers an array of advantages over conventional methods of cancer drug delivery. First, polymeric micelles permit the delivery of water-insoluble, hard to deliver, cancer drugs in a single, safe vehicle.
With a core technology that facilitates the safe, effective delivery of multiple anti-cancer agents, the Co-D Therapeutics Pipeline is as rich as the cancer chemotherapy arsenal itself.